Publications des 5 dernières années

1. Pannetier, D., et al., Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever. PLoS Negl Trop Dis, 2014. 8(1): p. e2637.
2. Reynard, S., et al., Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response. J Virol, 2014. 88(23): p. 13923-7.
3. Russier, M., et al., The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses. J Virol, 2014. 88(23): p. 13811-20.
4. Matheron, S., et al., Ebola: should we consider influenza vaccination? Lancet, 2014. 384(9959): p. 2023-4.
5. Kuhn, J.H., et al., Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses, 2014. 6(11): p. 4760-99.
6. Baize, S., et al., Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med, 2014. 371(15): p. 1418-25.
7. Salvetti, A. and S. Baize, [Viral zoonoses and emergence: research is just starting]. Med Sci (Paris), 2015. 31(12): p. 1055-6.
8. Baize, S., Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus. Curr Opin Virol, 2015. 10: p. 70-6.
9. Reusken, C., et al., Identification of essential outstanding questions for an adequate European laboratory response to Ebolavirus Zaire West Africa 2014. J Clin Virol, 2015. 62: p. 124-34.
10. Sagui, E., et al., Severe Ebola Virus Infection With Encephalopathy: Evidence for Direct Virus Involvement. Clin Infect Dis, 2015. 61(10): p. 1627-8.
11. Baize, S., Towards deep insight into Ebola virus disease. Lancet Infect Dis, 2015. 15(9): p. 991-992.
12. van Griensven, J., et al., Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies. N Engl J Med, 2016. 375(23): p. 2307-2309.
13. van Griensven, J., et al., Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med, 2016. 374(1): p. 33-42.
14. Sissoko, D., et al., Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med, 2016. 13(3): p. e1001967.
15. Sow, M.S., et al., New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors. J Infect Dis, 2016. 214(10): p. 1475-1476.
16. Mailles, A., et al., Strengthened Ebola surveillance in France during a major outbreak in West Africa: March 2014-January 2016. Epidemiol Infect, 2017. 145(16): p. 3455-3467.
17. Nguyen, T.H., et al., Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis, 2017. 11(2): p. e0005389.
18. Subtil, F., et al., Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea. Clin Infect Dis, 2017. 64(12): p. 1788-1790.
19. Vernet, M.A., et al., Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea. JCI Insight, 2017. 2(6): p. e88864.
20. Etard, J.F., et al., Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infect Dis, 2017. 17(5): p. 545-552.
21. Tartour, K., et al., Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs. PLoS Pathog, 2017. 13(9): p. e1006610.
22. Carnec, X., et al., A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. J Virol, 2018. 92(12).
23. Schaeffer, J., et al., Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells. PLoS Pathog, 2018. 14(11): p. e1007430.
24. Madelain, V., et al., Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nat Commun, 2018. 9(1): p. 4013.
25. Reynard, S., et al., Immune parameters and outcomes during Ebola virus disease. JCI Insight, 2019. 4(1).
26. Schaeffer, J., et al., Non-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa Virus. Viruses, 2019. 11(3).
27. Baillet, N., et al., Autophagy Promotes Infectious Particle Production of Mopeia and Lassa Viruses. Viruses, 2019. 11(3).
28. Mateo, M., et al., Fatal Case of Lassa Fever, Bangolo District, Cote d’Ivoire, 2015. Emerg Infect Dis, 2019. 25(9): p. 1753-1756.